Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Zitierte Literatur
Adler CH (1992) Treatment of restless legs syndrome with Gabapentin. Clin Neuopharmacol 20: 148–151
Alderson K, Holds JB, Anderson RL (1991) Botulinum-induced alteration of nerve-muscle interactions in the human orbicularis oculi following treatment for blepharospasm. Neurology 41: 1800–1805
Alesch F, Pinter MM, Helscher RJ et al. (1992) Stimulation of son’s disease. J Neurol Neurosurg Psychiatry 55: 566–571
Allen RP, Picchietti D, Hening WA et al. (2003) Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 4: 101–119
American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders, 3. Aufl, korrigiert
Aoki KR, Francis J, Hasanthi R, Leumer D (2003) Comparison of the therapeutic windows of different botulinum neurotoxin preparations in an animal model. 55th Academy of Neurology Meeting, P03.088
Arya DK (1994) Extrapyramidal symptoms with selective serotonin reuptake inhibitors. Br J Psychiatry 165: 728–733
Ayd F (1961) A survey of drug induced induced extrapyra midal reactions. JAMA 175: 1054–1060
Baas H, Beiske AG, Chika J et al. (1997) Catechol-O-methyltransferase inhibi tion with tolcapone reduces the »wearing off« phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 63: 421–428
Baas H, Deuschl D, Oertel W, Poewe W (1996) Medikamentöse Therapie der Parkinson-Krankheit. Dtsch Ärzteblatt 93: A-2470–2477
Baas H, Beiske AG, Ghika J Poewe W et al. (1997) Catechol-O-methyltransferase inhibition with tolcapone reduces the »wearing off« phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 63: 421–428
Bannister R, Mathias CJ (1992) Clinical features and investigation of the primary autonomic failure syndromes. In: Bannister R, Mathias CJ (eds) Autonomic failure. Oxford Univ Press, Oxford New York Tokyo, pp 531–547
Barclay CL, Lang AE (1997) Dystonia in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 62: 352–356
Barnes TRE, Brande WM (1985) Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 428: 874–878
Becker PM, Jamieson AO, Brown WD (1993) Dopaminergic agents in restless legs syndrome and periodic limb movements of sleep: Response and complications of extended treatment in 49 cases. Sleep 16: 713–716
Benabid AL, Pollak P, Gervason C et al. (1991) Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet 337: 403–406
Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S (2005) A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 64: 1949–1951
Bennett DA, Beckett LA, Murray AM et al. (1996) Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 334: 71–76
Bergman H, Wichmann T, DeLong MR (1990) Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249: 1436–1438
Biggins CA, Boyd JL, Harrop FM et al. (1992) A controlled, longitudinal study of dementia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 55: 566–571
Black SE (1996) Focal cortical atrophy syndromes. Brain Cogn 31: 188–229
Bonuccelli U, Ceravolo R, Salvetti S et al. (1997) Clozapine in Parkinson’s disease tremor. Effects of acute and chronic administration. Neurology 49: 1587–1590
Bower JH, Maraganore DM, McDonnell SK, Rocca WA (1997) Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 49: 1284–1288
Brashear A, Lew MF, Dykstra DD et al. (1999) Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 53: 1439–1446
Breidenbach MA, Brunger AT (2004) Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 432: 925–929
Brin MF, Lew MF, Adler CH et al. (1999) Safety and efficacy of Neuro Bloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 53: 1431–1438
Burke RE, Fahn S, Jankovic J et al. (1982) Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology 32: 1335–1346
Burke RE, Kang UJ, Jankovic J et al. (1989) Tardive akathisia: an analysis of clinical features and response to open thera peutic trials. Mov Disord 4: 157–175
Cardoso FE, Jankovic J (1993) Cocaine-related movement disorders. Mov Disord 8: 175–178
Castelon Konkiewitz E, Trender-Gerhard I, Kamm C et al. (2002) Service-based survey of dystonia in Munich. Neuroepidemiology 21: 202–206
Ceballos-Baumann AO (1994) Klinik und Therapie der Dystonien. Akt Neurol 21: 99–106
Ceballos-Baumann AO (1996) Dystonien. In: Conrad B, Ceballos-Baumann AO (Hrsg) Bewegungsstörungen in der Neurologie. Thieme, Stuttgart New York, S 89–140
Ceballos-Baumann AO (2001) Evidence-based medicine in botulinum toxin therapy for cervical dystonia. J Neurol 248(Suppl 1): 14–20
Ceballos-Baumann AO (2003) Die Rolle der EMG-Steuerung bei der Botulinumtoxin-Therapie. Klin Neurophysiol 34: 1–7
Ceballos-Baumann AO, Konstanzer A, Dengler R, Conrad B (1990a) Lokale Injektionen von Botulinum-Toxin A bei zervikaler Dystonie: Verlaufsbeobachtungen an 45 Patienten. Akt Neurol 17: 139–145
Ceballos-Baumann AO, Kummer R von, Eckert W, Weicker H (1990b) Controlled-release levodopa/benserazide (Madopar HBS): Clinical observations and levodopa and dopa mine plasma concentrations in fluctuating parkinsonian patients. J Neurol 237: 24–28
Ceballos-Baumann AO, Böhme G, Konstanzer A et al. (1992) Spasmodische Dysphonie: Klinik und Erfahrungen mit laryngealen Injektionen von Botulinum-Toxin. Otorhinolaryngologia nova 2: 33–38
Ceballos-Baumann AO, Obeso JA, Vitek JL et al. (1994) Restoration of thalamocortical activity following posteroventral pallidotomy in Parkinson’s disease. Lancet 344: 814–814
Ceballos-Baumann AO, Passingham RE, Marsden CD, Brooks DJ (1995a) Motor reorganisation in acquired hemidystonia: a PET activation study. Ann Neurol 37: 746–757
Ceballos-Baumann AO, Passingham RE, Warner T et al. (1995b) Overactivity of prefrontal and underactivity of motor cortical areas in idiopathic dystonia: a PET activa tion study. Ann Neurol 37: 363–372
Ceballos-Baumann AO, Beocker H, Bartenstein P et al. (1999) A PET study of subthalamic nucleus stimulation in Parkinson’s disease: Enhanced movement related activity of motor association cortex and decreased motor cortex resting activity. Arch Neurol (in press)
Ceballos-Baumann AO, Sheean G, Passingham RE et al. (to be published) Botulinum toxin does not reverse the cortical dysfunction associated with writer’s cramp: a PET study. Brain
Ceballos-Baumann AO, Kupsch A, Naumann M, Volkmann J (2002) Dystonie. In: http://www.dgn.org/leitl.shtml, Hrsg. Leitlinien der Deutschen Gesellschaft für Neurologie
Coleman RM (1982) Periodic movements in sleep (nocturnal myoclonus) and restless legs syndrome. In: Guilleminault C (ed) Sleeping and waking disorders: indications and techniques. Addison-Wesley, Menlo-park, pp 265–295
Comella C, Jankovic J, Leurgans S, Fan W, Chmura T, Group DS. Botulinum serotype A compared to B in cervical dystonia: Randomized, double-blind, parallel study
Davis BJ, Rajput A, Rajput ML et al. (2000) A randomized doubleblind placebo-controlled trial of iron in restless legs syndrome. Eur Neurol 49: 70–75
Deacon T, Schumacher J, Dinsmore J et al. (1997) Histological evidence of fetal pig neural cell survival after transplanta tion into a patient with parkinsons disease. Nat Med 3: 350–353
Deep-Brain-Stimulation-Study-Group (2001) Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson’s disease. N Engl J Med 345: 956–963
Deuschl G, Köster B (1996) Diagnose und Behandlung des Tremors. In: Conrad B, Ceballos-Baumann AO (Hrsg) Bewegungsstörungen in der Neurologie. Thieme, Stuttgart, S 222–253
Deuschl G, Toro C, Matsumoto J, Hallett M (1995) Movement related cortical potentials in writer’s cramp. Ann Neurol 38: 862–868
Ehrenberg BL, Eisensehr I, Corbett KE et al. (2000) Valproate for sleep consolidation in periodic limits movement disorder. J Clin Psychopharmacol 20: 574–578
Engel PA (1996) Treatment of progressive supranuclear palsy with amitriptyline: therapeutic and toxic effects. J Am Geriatr Soc 44: 1072–1074
Erbguth F, Benecke R, Ceballos-Baumann AO et al. (1995) Lokale Injektionsbehandlung fokaler Hyperkinesen mit Botulinum-Toxin A. Dtsch Ärzteblatt 92: B-2002–2008
Fahn S, Bressman SB, Marsden CD (1998) Classification of dystonia. Adv Neurol 78: 1–10
Fleischhacker WW, Miller CH, Bergmann KJ (1989) Die neuroleptikainduzierte Akathisie. Nervenarzt 60: 719–723
Ford B, Greene P, Louis ED et al. (1996) Use of intrathecal bac lofen in the treatment of patients with dystonia. Arch Neurol 53: 1241–1246
Friedman JH, Lannon MC (1990) Clozapine-responsive tremor in Parkinson’s disease. Mov Disord 5: 225–229
Ganzini L, Casey DE, Hoffman WF, McCall AL (1993) The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 153: 1469–1475
García-Ruiz PJ, Mena MA, Peñfiel N, García-de-Yebenes J (1992) Parkinsonism associated with calcium channel blockers: a prospective follow up study. Clin Neuropharmacol 15: 19–26
Ghika J, Bogousslavsky J (1997) Presymptomatic hypertension is a major feature in the diagnosis of progressive supra nuclear palsy. Arch Neurol 54: 1104–1108
Goodmann JDS, Brodie C, Ayida GA (1988) Restless legs syndrome in pregnancy. Br Med 297: 1101–1102
Greene P, Fahn S, Diamond B (1994) Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 9: 213–217
Gunne LM, Haggstrom JE, Sjoquist B (1984) Association of persistent neuroleptic-induced dyskinesia with regional changes in the brain GABA-synthesis. Nature 309: 347–349
Haussermann P, Marczoch S, Klinger C, Landgrebe M, Conrad B, Ceballos-Baumann A (2004) Long-term follow-up of cervical dystonia patients treated with botulinum toxin A. Mov Disord 19: 303–308
Hoehn MM (1992) The natural history of Parkinson’s disease in the pre-levodopa eras. Neurol Clin 10: 331–340
Hughes AJ, Lees AJ, Stern GM (1991) Challenge tests to predict the dopaminergic response in untreated Parkinson’s disease. Neurology 41: 1723–1725
Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181–184
Hughes AJ, Bishop S, Kleedorfer B et al. (1993) Subcutaneous apomorphine in Parkinson’s disease: response to chronic administration for up to five years. Mov Disord 8: 165–170
Jankovic J, Orman J (1988) Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 38: 391–394
Jeste DV, Caligiuri MP (1993) Tardive dyskinesia. Schizophr Bull 19: 303–315
Kane JM, Smith JM (1982) Tardive dyskinesia. Arch Gen Psychiatry 39: 473–481
Kappler J, Menges C, Ferbert A, Ebel H (1994) Schwere »Spät«ystonie nach »Neuroleptanxiolyse« mit Fluspirilen. Nervenarzt 65: 66–68
Kessler KR, Benecke RA (1997) The edb test: a clinical test for the detection of antibodies to botulinum toxin type a. Mov Disord 12: 95–99
Klinz C, Biesold K-H (1990) Familiäre paroxysmale dystone Choreoathetose. Nervenarzt 61: 507–509
Klockgether T, Jacobsen P, Löschmann PA, Turski L (1993) The antiparkinsonian agent budipine is an N-methyl-D-aspartate antagonist. J Neural Transm 5: 101–106
Klockgether T, Wullner U, Steinbach JP, Petersen V, Turski L, Loschmann PA (1996) Effects of the antiparkinsonian drug budipine on central neurotransmitter systems. Eur J Pharmacol 301: 67–73
Koller W, Pahwa R, Busenbark K et al. (1997) High-frequency unilateral thalamic stimulation in the treatment of essenzial and parkinsonian tremor. Ann Neurol 42: 292–299
Költgen D, Ceballos-Baumann AO, Franke C (1994) Botulinum toxin converts muscle acetylcholine receptors from adult to embryonic type. Muscle Nerve 17: 779–784
Kornhuber J (1989) Memantine displaces (3H) MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol 166: 589–590
Krack P, Pollak P, Limousin P et al. (1988) Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson’s disease. Brain 121: 451–457
Krack P, Batir A, Van Blercom N et al. (2003) Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med 349: 1925–1934
Krack P, Batir A, Van Blercom N et al. (2003) Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med 349: 1925–1934
Kurth MC, Adler CH, Sthilaire M et al. (1997) Tolcapone improves motor function and reduces levodopa requirement in patients with parkinsons disease experiencing motor fluctuations: a multicenter, double blind, randomized, placebo controlled trial. Neurology 48: 81–87
Lang AE (1987) Restless legs syndrome and Parkinson’s disease: insights into pathophysiology. Clin Neuropharmacol 10: 474–478
Lange DJ, Rubin M, Greene PE et al. (1991) Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes. Muscle Nerve 14: 672–675
Lavigne GJ, Montplaisir JY (1994) Restless legs syndrome and sleep bruxism: Prevalence and association among Canad ians. Sleep 17: 739–743
Lazaro RP (1982) Involuntary movement disorders induced by anticonvulsant drugs. Mount Sinai J Med 49: 274–281
Leube B, Rudnicki D, Ratzlaff T et al. (1996) Idiopathic torsion dystonia: assignment of a gene to chromosome 18p in a german family with adult onset, autosomal dominant inheritance and purely focal distribution. Human Molec Gen 5: 1673–1677
Lew MF, Adornato BT, Duane DD et al. (1997) Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 49: 701–707
Lieberman JA, Saltz BL, Johns CA et al. (1991) The effects of clozapine on tardive dyskinesia. Br J Psychiatry 158: 503–510
Limousin P, Pollack P, Benazzouz A et al. (1995) Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 91–95
Lindvall O, Sawle G, Widner H et al. (1994) Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson’s disease. Ann Neurol 35: 172–180
Litvan I, Agid Y, Calne D et al. (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47: 1–9
Lopez OL, Wisnieski SR, Becker JT et al. (1997) Extrapyramidal signs in patients with probable Alzheimer disease. Arch Neurol 54: 969–975
Lowenstein DH, Aminoff MJ (1988) The clinical course of spasmodic torticollis. Neurology 38: 530–532
Lozano AM, Lang AE, Galvez JN et al. (1995) Effect of GPi pallidotomy on motor function in Parkinson’s disease. Lancet 346: 1383–1387
Marchetti A, Magar R, Findley L et al. (2005) Retrospective evaluation of the dose of dysport and BOTOX in the management of cervical dystonia and blepharospasm: The REAL DOSE study. Mov Disord
Marsden CD, Jenner P (1980) The pathophysiology of extrapyra midal side-effects of neuroleptic drugs. Psychol Med 10: 55–72
Marsden CD, Quinn NP (1990) The dystonias. BMJ 300: 139–144
McKeith IG, Galasko D, Kosaka K et al. (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47: 1113–1124
Mejia NI, Vuong KD, Jankovic J (2005) Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 20: 592–597
Montastruc JL, Rascol O, Rascol A (1989) A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: A 3 year follow-up. J Neurol Neurosurg Psychiatry 52: 773–775
Morgenstern H, Glazer WM (1993) Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry 50: 723–733
Moshagen V, Moschner C, Wessel K (2003) Wertigkeit neurophysiologischer Verfahren bei der Differenzialdiagnose der Systematrophien. Klin Neurophysiol 34: 55–64
Nitschke MF, Kleinschmidt A, Wessel K, Frahm J (1996) Somatotopic organization of the human anterior cerebellum as detected by functional magnetic resonance neuroimaging Brain 119: 1023–1029
Nitschke MF, Hahn C, Melchert UH, Handels H, Wessel K (1998) Activation of the cerebellum by sensory finger stimulation and by finger opposition movements: A functional magnetic resonance imaging study. J Neuroimaging 8: 127–131
Nomoto M, Thompson PD, Sheehy MP et al. (1987) Anticholinergicinduced chorea in the treatment of focal dystonia. Mov Disord 2: 53–56
Nutt JG, Muenter MD, Aronson A et al. (1988) Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord 3: 188–194
Nygaard TG, Marsden CD, Fahn S (1991) Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology 41: 174–181
Obeso JA, Guridi J, Delong M (1997) Surgery for parkinsons disease. J Neurol Neurosurg Psychiatry 62: 2–8
Oertel W (1996) Multisystematrophie. In: Conrad B, Ceballos-Baumann AO (Hrsg) Bewegungsstörungen in der Neurologie. Thieme, Stuttgart New York, S. 69–77
Oppenheim H (1911) Über eine eigenartige Krampfkrankheit des kindlichen und jugendlichen Alters (dysbasia lordotica progressiva, dystonia musculorum deformans). Neurologie Zentralblatt 30: 1090–1107
Parkinson-Study Group (2003) A controlled trial of rotigotine monotherapy in early Parkinson’s disease. Arch Neurol 60(12): 1721–1728
Pfeiffer RF, Kang J, Graber B et al. (1990) Clozapine for psychosis in Parkinson’s disease. Mov Disord 5: 239–242
Poewe WH, Lees AJ, Stern GM (1986) Low-dose L-dopa therapy in Parkinson’s disease: A 6-year follow-up study. Neurology 36: 1528–1530
Poewe W, Schelosky L, Kleedorfer B et al. (1992) Treatment of spasmodic torticollis with local injections of botulinum toxin. One-year follow-up in 37 patients. J Neurol 239: 21–25
Poewe W, Ceballos-Baumann AO, Conrad B (1996) Parkinson-Krankheit. In: Conrad B, Ceballos-Baumann AO (Hrsg) Bewegungsstörungen in der Neurologie. Thieme, Stuttgart, S 30–60
Polymeropoulos MH, Higgins JJ, Golbe LI et al. (1996) Mapping of a gene for Parkinson’s disease to chromosome 4q21-q23. Science 274: 1197–1199
Poulain B, Tauc L, Maisey EA, Wadsworth JD, Mohan PM, Dolly JO (1988) Neurotransmitter release is blocked intracellularly by botulinum neurotoxin, and this requires uptake of both toxin polypeptides by a process mediated by the larger chain. Proc Natl Acad Sci U S A 85: 4090–4094
Przuntek H, Bittkau S, Bliesath H et al. (2002) Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen. Arch Neurol 59: 803–806
Quinn N (1994) Multiple system atrophy. In: Marsden CD, Fahn S (eds) Movement disorders 3. Butterworth Heinemann, Oxford, pp 263–281
Quinn NP (1996) Review: essenzial myoclonus and myoclonic dystonia. Mov Disord 11: 119–126
Raja M (1995) Tardive dystonia. Prevalence, risk factors, and comparison with tardive dyskinesia in a population of 200 acute psychiatric patients. Eur Arch Psych Clin Neurosci 145–151
Rebeiz JJ, Kolodny EH, Richardson EP (1968) Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 18: 20–33
report NioHC (1991) Clinical use of botulinum toxin. National Insti tutes of Health consensus development. Arch Neurol 48: 1294–1298
Riley D, Lang AE, Blair RDG et al. (1988) Frozen shoulder and other shoulder abnormalities in Parkinson’s disease. J Neurol Neurosurg Psychiatry 52: 63–66
Rinne UK (1989) Lisuride, a dopamine agonist in the treatment of early Parkinson’s disease. Neurology 39: 336–339
Rinne UK, Bracco F, Chouza C et al. (1997) Cabergoline in the treatment of early parkinsons disease: results of the first year of treatment in a double blind comparison of cabergoline and levodopa. Neurology 48: 363–368
Rinne UK, Larsen JP, Siden A, Worm-Petersen J (1998) Enta capone enhances the response to levodopa in parkinsonian patients with motor fluctruations. Nomecomt Study Group. Neurology 51: 1309–1314
Roggenkamper P, Jost WH, Bihari K, Comes G, Grafe S (2005) Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm
Rothdach A, Trenkwalder C, Haberstock J et al. (2000) Prevalence and risk factors of RLS in an elderly population: The MEMO study. Neurology 54: 1064–1068
Saint HM, Burke RE, Bressman SB et al. (1991) Delayed-onset dystonia due to perinatal or early childhood asphyxia. Neurology 41: 216–222
Salih AM, Gray RES, Mills KR, Webley M (1994) A clinical, serological and neurophysiological study of restless-legs syndrome in rheumatoid arthritis. Br J Rheumatol 33: 60–63
Saudou F, Finkbeiner S, Devys D, Greenberg M (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95: 55–66
Schanz EJ, Johnson EA (1992) Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 1992: 80–99
Schrag A, Ben-Shlomo Y, Quinn N (2002) How common are complications of Parkinson’s disease? J Neurol 249: 419–423
Schwarz M, Noth J (1999) Chorea und Ballismus. In: Hopf HC, Deuschl G, Diener HC, Reichmann H (Hrsg) Neurologie in Klinik und Praxis, Thieme, Stuttgart New York, S 78–86
Schwarz J, Tatsch K, Arnold G (1992) 123-Iodobenyamide-SPECT predicts dopaminergic responsiveness in patients with »de novo« Parkinsonism. Neurology 42: 556–561
Sheehy MP, Marsden CD (1982) Writers’ cramp-a focal dystonia. Brain 105: 461–481
Siatkowski RM, Tyutyunikov A, Biglan AW et al. (1993) Serum antibody production to botulinum A toxin. Ophthalmology 100: 1861–1866
Siegfried J, Lippitz B (1994) Bilateral chronic electrostimula tion of ventroposterolateral pallidum: a new therapeutic approach for alleviat ing all parkinsonian symptoms. Neurosurgery 35: 1126–1129
Spieker S, Loschmann PA, Klockgether T (1999) The NMDA antagonist budipine can alleviate levodopa-induced motor fluctuations. Mov Disord 14: 517–519
Steele JC, Richardson JC, Olszewski J (1964) Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 10: 333–358
Steele J, Faulds D, Sorkin EM (1993) Tiapride: A review of its pharmacodynamic properties and therpeutic potenzial in geriatric population. Drugs & Aging 3: 460–478
Stein MB, Heuser IJ, Juncos JL, Uhde TW (1990) Anxiety dis orders in patients with Parkinson’s disease. Am J Psychiatry 147: 217–220
Sweet C (1975) Drug induced dystonia. Am J Psychiatry 132: 532–533
Tanaka M, Hirai S, Kondo S et al. (1998) Cerebral hypoperfusion and hypometabolism with altered striatal signal intensity in choreaacanthocytosis: a combined PET and MRI study. Mov Disord 13: 100–107
Tanner CM (1994) Epidemiological clues to the cause of Parkinson’s disease. In: Marsden CD (eds) Movement dis orders 3. Butterworths London, pp 124–146
Taylor TD, Litt M, Kramer P et al. (1996) Homozygosity mapping of Hallervorden-Spatz syndrome to chromosome 20p12.3–p13 [published erratum appears in Nat Genet 1997 May;16(1):109]. Nat Genet 14: 479–481
The Parkinson Study Group (1999) Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med 340: 757–763
Trenkwalder C, Stiasny K, Oertel WH (1996) Therapie des idiopathischen und urämischen Restless-legs-Syndroms. Nervenarzt 67: 265–276
Trosch RM, Friedman JH, Lannon MC et al. (1998) Clozapine use in Parkinson’s disease: a retrospective ana lysis of a large multicentered clinical experience. Mov Disord 13: 377–382
Tyne HL, Parsons J, Sinnott A, Fox SH, Fletcher NA, Steiger MJ (2004) A 10 year retrospective audit of long-term apomorphine use in Parkinson’s disease. J Neurol 251: 1370–1374
Verhagen Metman L, Del Dotto P, van den Munckhof P et al. (1998) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology 50: 1323–1326
Vidailhet M, Vercueil L, Houeto JL et al. (2005) Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. N Engl J Med 352: 459–467
Waddy HM, Fletcher NA, Harding AE, Marsden CD (1991) A genetic study of idiopathic focal dystonias. Ann Neurol 29: 320–324
Walshe JM, Yealland M (1992) Wilson’s disease: the problem of delayed diagnosis. J Neurol Neurosurg Psychiatry 55: 692–696
Walters AS, Picchietti D, Hening WA, Lazzarini A (1990) Variable expression in familial restless legs syndrome. Ann Neurol 47: 1219–1220
Walters AS and the International Restless-legs-Syndrome Study Group (1995) Towards a better definition of the restless legs syndrome. Mov Disord 10: 634–642
Walters AS, Hickey K, Maltzman J et al. (1996) A questionnaire study of 138 patients with restless legs syndrome: The »Night-Walkers« survey. Neurology 46: 92–95
Wenning GK, Pramstaller PP, Ransmayr G, Poewe W (1997) Atypische Parkinson-Syndrome. Nervenarzt 68: 102–115
Wessel K, Diener HC, Dichgans J, Thron A (1988) Cerebellar dysfunction in patients with bronchogenic carcinoma: clinical and posturographic findings. J Neurol 235: 290–296
Wessel K, Schroth G, Diener HC et al. (1989) Significance of MRI-confirmed atrophy of the cranial spinal cord in Fried reich’s ataxia. Eur Arch Psychiatr Neurol Sci 238: 225–230
Wessel K (2003) Transcranial magnetic brain stimulation and the cerebellum. Transcranial magnetic stimulation and transcranial direct current stimulation. Clin Neuophysiol (Suppl.) 56: 441–445
Wessel K, Verleger R, Nazarenus D, Vieregge P, Kömpf D (1994) Movement-related cortical potenzials preceding sequenzial and goaldirected finger movements in patients with cerebellar atrophy. Electroenceph Clin Neurophysiol 92: 331–341
Wessel K, Hermsdörfer J, Deger K et al. (1995a) Double-blind cross over study with L-5-hydroxy tryptophane in patients with degenerative cerebellar diseases. Arch Neurol 52: 451–455
Wessel K, Zeffiro T, Lou JS, Toro C, Hallet M (1995b) Regional cerebral blood flow during a self-paced sequenzial finger opposition task in patients with cerebellar degeneration. Brain 118: 379–393
Wessel K, Tegenthoff M, Vorgerd M et al. (1996) Enhanced inhibitory mechanisms in the motor cortex of patients with cerebellar degeneration: A study with transcranial magnetic brain stimulation. Electroenceph clin Neurophysiol 101: 273–281
Wissel J, Kabus C, Wenzel R et al. (1996) Botulinum toxin in writers cramp: objective response evaluation in 31 patients. J Neurol Neurosurg Psychiatry 61: 172–175
Wolf SS, Jones DW, Knable MB et al. (1996) Tourette syndrome: prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding. Science 273: 1225–1227
Zimprich A, Grabowski M, Asmus F et al. (2001) Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. Nat Genet 29: 66–69
Weiterführende Literatur
Albin RL, Young AB, Penney JB (1989) The functional anatomy of disorders of the basal ganglia disorders. Trends Neurosc 12: 366–375
Alesch F, Pinter MM, Helscher RJ et al. (1995) Stimulation of the ventral intermediate thalamic nucleus in tremor dominated Parkinson’s disease and essenzial tremor. Acta Neurochir Wien 136: 75–81
Arendt G, Hefter H, Stremmel W, Strohmeyer G (1994) The diagnostic value of multi-modality evoked potenzials in Wilson’ s disease. Electromyogr Clin Neurophysiol 34: 137–148
Bain PG (1993) A combined clinical and neurophysiological approach to the study of patients with tremor. J Neurol Neurosurg Psychiatry 69: 839–844
Bhatia KP, Brown P, Gregory R et al. (1995) Progressive myo clonic ataxia associated with coeliac disease. Brain 118: 1087–1093
Boecker H, Wills A, Ceballos-Baumann AO et al. (1996) The functional effect of ethanol on alcohol-responsive essenzial tremor. Ann Neurol 39: 650–658
Bonelli RM, Wenning GK, Kapfhammer HP (2004) Huntington’s disease: present treatments and future therapeutic modalities. Int Clin Psychophamacol 19: 51–62
Braune S, Reinhardt M, Schnitzer R et al. (1999) Cardiac uptake of [123J]MIBG separates Parkinson’s disease from multiple system atrophy. Neurology 53: 1020–1025
Breedveld GJ, Percy AK, MacDonald ME et al. (2002) Clinical and genetic heterogeneity in benign hereditary chorea. Neurology 59: 579–584
Brewer GJ, Yuzbasian-Gurkan V (1992) Wilson’s disease. Medicine 71: 139–164
Brewer GJ, Johnson V, Dick RD (1996) Treatment of Wilson disease with ammonium tetrathiomolyb-date. Arch Neurol 53: 1017–1025
Brewer GJ, Hedera P, Kluin KJ et al. (2003) Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 60: 379–385
Bruyn GW, Went LN (1986) Huntington’s chorea. In: Vinken PJ, Bruyn GW, Klawans HL (eds) Handbook of Clinical Neurology, vol 49, Elsevier, Amsterdam New York, pp 267–314
Bürk K, Abele M, Fetter M et al. (1996) Autosomal dominant cerebellar ataxia typ I. Clinical features and MRI in families with SCA1, SCA2 and SCA3. Brain 119: 1497–1505
Ceballos-Baumann AO (1995) Medikamentös induzierte Dyskinesien. Akt Neurol 22: 245–257
Ceballos-Baumann AO (1996a) Dystonien. In: Conrad B, Ceballos-Baumann AO (Hrsg) Bewegungsstörungen in der Neurologie. Thieme, Stuttgart, S 89–140
Ceballos-Baumann AO (1996b) Medikamentös induzierte Bewegungsstörungen. In: Conrad B, Ceballos-Baumann AO (Hrsg) Bewegungsstörungen in der Neurologie. Thieme, Stuttgart, S 308–332
Ceballos-Baumann AO, Conrad B (1994a) Essenzieller Tremor. Münch Med Wochenschr 136: 196–198
Ceballos-Baumann AO, Conrad B (1994b) Tourette-Syndrom und Tic-Störungen. Münch Med Wschr 136: 277–280
Cha JH (2000) Transcriptional dysregulation in Huntington’s disease. Trends Neurosci 23: 387–392
Church AJ, Dale RC, Cardoso F et al. (2003) CSF and serum immune parameters in Sydenham’s chorea: evidence of an autoimmune syndrome? J Neuroimmunol 136: 148–153
Colosimo C, Albanese A, Hughes AJ, de Bruin VMS, Lees AJ (1995) Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson’s disease. Arch Neurol 52: 294–298
Conrad B (1996) Tics/Tourette-Syndrom. In: Conrad B, Ceballos-Baumann AO (Hrsg) Bewegungsstörungen in der Neurologie. Thieme, Stuttgart New York, S 186–221
Conrad B (2005) Wilson-Krankheit. In: Ceballos-Baumann AO, Conrad B (Hrsg) Bewegungsstörungen in der Neurologie. Thieme, Stuttgart New York, S 181–194
Danek A (1998) Restless-legs-Syndrom. In: Brandt T, Dichgans J, Diener HC (Hrsg) Therapie und Verlauf neurologischer Erkrankungen, 3. Aufl. Kohlhammer, Stuttgart Berlin Köln, S 935–940
Danek A (2002) Fortschritte in der molekularen Choreadiagnostik: McLeod-Syndrom und Chorea-Akanthozytose. Nervenarzt 73: 564–569
Diener HC, Dichgans J, Bacher M, Guschlbauer B (1984) Improvement of ataxia in alcoholic cerebellar atrophy through alcohol abstinence. J Neurol 231: 258–262
Fahn S (1994) The paroxysmal dyskinesias. In Marsden CD, Fahn S (eds) Movement Disorders 3. Butterworth-Heinemann, Oxford, 310–345
Fahn S, Bressman S, Marsden CD (to be published) Classification of dystonia. Adv Neurol
Geissler I, Heinemann K, Rohm S, Hauss J, Lamesch P (2003) Liver transplantation for hepatic and neurological Wilsons disease. Transplant Proc 35: 1445–1446
Gilman S et al. (1999) Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 163: 94–98
Hardie RJ, Pullon HWH, Harding AE et al. (1991) Neuroacan thocytosis. A clinical, haematological and pathological study of 19 cases. Brain 114: 13–49
Harding A (1995) Inherited ataxias. Curr Opin Neurol 8: 306–309
Huntington Study Group (2001) A randomised, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease. Neurology 57: 397–404
Huntington’s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72: 971–983
Khoshnan A, Ko J, Patterson PH (2002) Effects of intracellular expression of antihuntington antibodies of various specificities on mutant Huntington aggregation and toxicity. Proc Natl Acad Sci USA 99: 1002–1007
Kimber JR, Watson L, Mathias CJ (1997) Distinction of idiopathic Parkinson’s disease from multiple-system atrophy by stimulation of growth-hormone release with clonidine. Lancet 349: 1877–1881
Klockgether T, Döller G, Wüllner U, Petersen D, Dichgans J (1993) Cerebellar encephalitis in adults. J Neurol 240: 17–20
Klockgether T, Wüllner U, Dichgans J et al. (1993) Clinical and imaging correlations in inherited ataxias. Adv Neurol 61: 77–96
Lajonchere C, Nortz M, Finger S (1996) Gilles de la Tourette and the discovery of Tourette syndrome. Arch Neurol: 567–574
Lang AE (1994) Withdrawal akathisia: case reports and a proposed classification of chronic akathisia. Mov Disord 9: 188–192
Lees AJ (1985) Tics and related disorders. Churchill Living stone, Edinburgh
Menkes JH (1995) Disorders of mental metabolism. In: Rowland LP (ed) Merrits’s Textbook of Neurology. Williams & Wilkins, Baltimore, pp 584–589
Müller N, Putz A, Straube A, Kathmann N (1995) Zwangsstörung und das Gilles-de-la-Tourette-Syndrom. Über die Differenzialdiagnose von organischen und psychogenen Symptomen. Nervenarzt 66: 372–378
Padberg G, Bruyn GW (1986) Chorea: differential diagnosis. In: Vinken PJ, Bruyn GW, Klawans HL (eds) Handbook of Clinical Neurology, vol 49. Elsevier, Amsterdam New York, pp 549–555
Ranen NG, Stine OC, Abbott MH et al. (1995) Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington Disease. Am J Hum Genet 57: 593–602
Rosenberg RN (1995) Autosomal dominant cerebellar phenotypes. The genotype has settled the issue. Neurology 45: 1–5
Ross (2004) Huntington’s disease: a new paths to pathogenesis. Cell 118: 4–7
Sambrook MA, Crossmann AR, Mitchell IJ (1994) Experimental models of basal ganglia disease. Mov Disord 3: 28–45
Schmidt HH-J (2003) Diagnostik und Therapie des Morbus Wilson. Dtsch Ärztebl 100: A192–197
Sharp AH, Ross CA (1996) Neurobiology of Huntington’s disease. Neurobiol Disease 3: 3–15
Stracciari A, Tempestini A, Borghi A, Guarino M (2000) Effect of liver transplantation on neurological manifestations in Wilson disease. Arch Neurol 57: 384–386
Tanzi RE, Petrukhin K, Chernov I (1993) The Wilson’s disease gene is a copper-transporting ATPase with homology to the Menkes disease gene. Nature Genet 5: 344–350
Walshe JM (1986) Wilson’s disease. In: Vinken PJ, Bruyn GW, Klawans HL (eds) Handbook of Clinical Neurology, vol 49. Elsevier, Amsterdam New York, pp 549–555
Watanabe H, Saito Y, Terao S (2002) Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 125: 1070–1083
Weiland T, Wessel K (2005) Ataxien. Fortschr Neurol Psychiatr 73: 286–299
Weindl A, Conrad B (1996) Chorea und choreatische Bewegungsstörungen. In: Conrad B, Ceballos-Baumann AO (Hrsg) Bewegungsstörungen in der Neurologie, Thieme, Stuttgart New York, S 155–180
Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP (1997) Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 12: 133–147
Wenning GK, Colosimo C, Geser F et al. (2004) Multiple system atrophy. Lancet Neurol 3: 93–103
Wessel K, Kömpf D (1988) Paraneoplastic cerebellar degeneration in patients with bronchogenic carcinoma. Prog Clin Neurosci 2: 43–55
Wessel K, Huss HP, Brückmann H, Kömpf D (1993) Follow-up of neurophysiological tests and CT in late-onset cerebellar ataxia and multiple system atrophy. J Neurol 240: 168–176
Wessel K, Moschner C, Wandinger KP, Kömpf D, Heide W (1998) Oculomotor testing in the differential diagnosis of degenerative ataxic disorders. Arch Neurol 55: 949–956
Winkelmann MD, Hines JD (1983) Cerebellar degeneration caused by high-dose cytosine arabinoside: A clinicopa thological study. Ann Neurol 14: 520–527
Wittkämper A, Wessel K, Brückmann H, Kömpf D (1993) CT-morphology in patients with autosomal dominant or idiopathic cerebellar ataxia. Neuroradiology 35: 520–524
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Ceballos-Baumann, A.O., Schwarz, M., Wessel, K., Meyring, S. (2006). Bewegungsstörungen. In: Berlit, P. (eds) Klinische Neurologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-31176-9_39
Download citation
DOI: https://doi.org/10.1007/3-540-31176-9_39
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-01982-4
Online ISBN: 978-3-540-31176-8
eBook Packages: Medicine (German Language)